3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow BGB-283: new trials by email Literature Review of BGB-283 trials Research Report on BGB-283
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Lifirafenib, mirdametinib - Solid Tumor, Adult | Phase 1 | Completed | BeiGene | 91 | 2019-05-01 | 2026-01-07 |
| The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor BGB-283 - Solid Tumors | Phase 1 | Completed | BeiGene | 42 | 2015-10-12 | 2024-10-23 |
| Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors BGB-283 - Solid Tumors | Phase 1 | Completed | BeiGene | 131 | 2013-11-20 | 2024-12-27 |
BeiGene (3)
Australia (2) · China (1) · New Zealand (1) · United States (1)
Jayesh Desai, MD (1) · Xiang Li, MD (1)